Arcturus Q2 revenue falls sharply on CSL Seqirus deal end

Arcturus Therapeutics Holdings

06/08/2026 21:12

Overview
Messenger RNA medicines company's Q2 revenue fell sharply yr/yr due to CSL Seqirus collaboration termination
Q2 net loss widened yr/yr, reflecting ongoing clinical development costs
Company received $12 mln cash and $16 mln in released liabilities and R&D credits from CSL Seqirus settlement

Outlook
Company expects decision on advancing ARCT-032 to Phase 3 in Q4 2026
Arcturus plans to communicate ARCT-810 data and regulatory plan in Q3 2026
Company intends to evaluate development and partnering opportunities for infectious disease vaccine portfolio

Result Drivers
CSL SEQIRUS TERMINATION - Revenue declined due to reduced revenue recognized from CSL Seqirus collaboration as co moved toward terminating the agreement
LOWER R&D SPENDING - Decreased research and development expenses driven by reduced salaries, wages, benefits and facilities costs as co focused on highest-priority programs
CLINICAL PROGRAM PROGRESS - Ongoing enrollment in ARCT-032 and completed dosing in ARCT-810 contributed to continued clinical development costs

Company press release: ID:nBw9048CLa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
 
$880,000
 
Q2 Net Loss
 
$23.79 mln
 
Q2 Loss Per Basic Share
 
$0.84
 
Q2 Operating Expenses
 
$28.50 mln
 
Q2 Operating Income
 
-$25.55 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Arcturus Therapeutics Holdings Inc is $20.00, about 219.5% above its August 5 closing price of $6.26

Reuters Recommended Reads
Aug 6 - US FDA approves first mRNA flu shot from Moderna
Aug 6 - Novavax raises annual revenue forecast as licensing bets offset weak vaccine demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)